Mark Wiggins
Corporate Officer/Principal en VAXCYTE, INC. .
Perfil
Mark C.
Wiggins is currently the Director at selectION, Inc. and the Chief Business Officer at Vaxcyte, Inc. Previously, he held positions such as Marketing Director at Schering Corp., Independent Director at Zogenix, Inc., Head-Business Development at Schering-Plough Corp., Vice President-Marketing at Idera Pharmaceuticals, Inc., Executive VP-Corporate & Business Development at Biogen, Inc., Chief Business Officer at TRACON Pharmaceuticals, Inc., Senior VP-Corporate & Business Development at Elcelyx Therapeutics, Inc., and Principal at Johnson & Johnson Innovation - JJDC, Inc. He also served as Vice President-Marketing & Business Development at IDEC Pharmaceuticals Corp., Executive Vice President at Biogen Idec New Ventures, Inc., and Chief Business Officer at MPEX Pharmaceuticals, Inc. Mr. Wiggins obtained an undergraduate degree from Syracuse University and an MBA from the University of Arizona.
Cargos activos de Mark Wiggins
| Empresas | Cargo | Inicio |
|---|---|---|
| VAXCYTE, INC. | Corporate Officer/Principal | 11/10/2022 |
selectION, Inc.
 selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | Director/Miembro de la Junta | 01/01/2018 |
Antiguos cargos conocidos de Mark Wiggins.
| Empresas | Cargo | Fin |
|---|---|---|
| TRACON PHARMACEUTICALS, INC. | Contacto de Relaciones con Inversores | 30/09/2022 |
| ZOGENIX, INC. | Director/Miembro de la Junta | 07/03/2022 |
Elcelyx Therapeutics, Inc.
 Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/03/2015 |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/01/2011 |
| BIOGEN INC. | Corporate Officer/Principal | 01/02/2009 |
Formación de Mark Wiggins.
| Syracuse University | Undergraduate Degree |
| University of Arizona | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| TRACON PHARMACEUTICALS, INC. | Health Technology |
| VAXCYTE, INC. | Health Technology |
| Empresas privadas | 10 |
|---|---|
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Finance |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Finance |
Schering Corp.
 Schering Corp. Pharmaceuticals: MajorHealth Technology Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY. | Health Technology |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | Health Technology |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Health Technology |
selectION, Inc.
selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Mark Wiggins
